Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford treatment.

Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion of the ways patients with a prescription can access the drug. The agreement means Ro has ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens, it framed the move as a way ...

The recalled product, packaged in single dose 10ml vials, can be identified from its lot code, '24020027,' and expiry date, December 2025. It also has the national drug code (NDC) '81284-213-01.' ...

The FDA clarifies that both Mounjaro single-dose vial products, which were approved in July 2023 (supplement to NDA 215866), and Zepbound single-dose vials, which were approved in March 2024 ...

Zepbound is available as a liquid solution in prefilled auto-injector vials or pens ... own within a few days of injecting your Zepbound dose. But, if you experience a reaction that’s severe ...

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...

Results from a separate trial that were released in 2022 showed patients taking a high dose of Lilly's (LLY.N), opens new tab Zepbound saw more than 20% weight loss. "The results give us greater ...